Hamlet Pharma | Lund is an innovative pharmaceutical company formed through the merger of Hamlet Pharma AB and SelectImmune Pharma AB. With a broad and strong portfolio of projects, they focus on developing new therapeutic solutions for the treatment of cancer and infections. Hamlet Pharma also acquired additional patent rights for the treatment of tuberculosis.

Their parent compound, HAMLET, has shown broad anti-tumor effects in animal models and clinical trials. They have a second-generation synthetic drug candidate called Alpha1H, which has demonstrated the ability to kill a variety of cancer cells in controlled clinical trials. They are also developing Bovine HAMLET (BAMLET) for clinical trials in colon cancer and oral cancer.

The company is part of the European Union Horizon 2020 program and has a robust IP portfolio with about 50 patents and patent applications worldwide. Hamlet Pharma is actively seeking partnerships and investments to bring their innovative drugs to the market